NASDAQ · SYRE
Spyre Therapeutics, Inc.
$95.72-$3.24 (-3.27%)
Spyre Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 13.14% below the high.
Loading market information…
NASDAQ · SGTX · USD
Stock price, earnings
Quote as of Aug 10, 2023, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Sigilon Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 19.75% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Sigilon Therapeutics, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Cambridge, Massachusetts-based Sigilon Therapeutics, Inc., established in 2015, functions as a clinical-stage biotechnology firm dedicated to creating lasting solutions for patients grappling with chronic health conditions. Its primary investigational therapy, SIG-001, is currently undergoing Phase I/II clinical assessment to prevent bleeding episodes in individuals suffering from moderate to severe Hemophilia A. The company's research pipeline also encompasses SIG-005, designed to address the non-neurological symptoms associated with mucopolysaccharidosis type 1; SIG-007, engineered to ensure a continuous and sustained delivery of functional enzymes sufficient to generate clinical improvements and halt the advancement of Fabry disease; and SIG-002, an initiative focused on replacing islet cells for the treatment of Type 1 Diabetes. Furthermore, Sigilon Therapeutics holds a collaborative research and licensing agreement with Eli Lilly and Company for the advancement and market release of SLTx product candidates targeting Type 1 Diabetes. Originally known as Sigilon, Inc., the company officially adopted its current name in June 2017.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:21 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| -$7.15-19.57% vs estimate |
| $1.99M-0.5% vs estimate |
| Q3 2021 | Nov 10, 2021 | -$8.19+8.7% vs estimate | $1.95M-8.0% vs estimate |
|---|
THE ANALYST VIEW
5 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$95.72-$3.24 (-3.27%)
Spyre Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 13.14% below the high.
$1.07-$0.01 (-0.93%)
Surface Oncology, Inc.’s quoted price sits in the upper half of its reported 52-week range, 25.17% below the high.
$2.38+$0.01 (+0.42%)
Heat Biologics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 4.03% below the high.
$18.20+$16.47 (+952.02%)
Reneo Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 78.05% below the high.
$1.48+$0.01 (+0.68%)
Achilles Therapeutics plc’s quoted price sits in the upper half of its reported 52-week range, 1.99% below the high.
$0.68-$0.05 (-6.41%)
Rein Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 68.81% below the high.
$1.48$0.00 (0.0%)
TCR2 Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 61.86% below the high.
$0.88+$0.01 (+1.49%)
Kronos Bio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 39.73% below the high.
